Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Trends Report 2025 – For Business Development and Strategy Teams
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Growth in 2025?
In recent times, the market size for the treatment of chronic obstructive pulmonary disease (COPD) has seen robust growth. It’s expected to expand from a value of $20.84 billion in 2024 to reach $21.94 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 5.3%. The historical growth pattern can be traced back to factors such as the widespread smoking and tobacco use, innovative advancements in inhalation therapies, early diagnosis through awareness programs, government-led respiratory health initiatives, and active research and advancement in pulmonology.
What Is the Forecast for the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size Through 2029?
Looking ahead, the market for chronic obstructive pulmonary disease (COPD) treatment is set to experience significant growth. It is predicted to expand to a whopping $27.74 billion by 2029, registering a compound annual growth rate (CAGR) of 6.0%. This anticipated growth over the forecast period is largely credited to factors such as developments in personalized medicine and biomarker research, biological treatments and targeted interventions, concerns over air quality and environmental influences, worldwide initiatives for smoking cessation, and partnerships for medication development. Key trends projected for this period encompass the rising use of digital health solutions for managing COPD, the advancement of biologic therapies for COPD, personalized medicine breakthroughs, the integration of combination therapies and inhalers, early detection and intervention methods, and the proliferation of pulmonary rehabilitation programs.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10054&type=smp
What are the Key Market Players in Chronic Obstructive Pulmonary Disease (COPD) Treatment Market and How They’re Evolving?
Major companies operating in the chronic obstructive pulmonary disease (COPD) treatment market include Almirall S.A., AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Abbott Laboratories, Chiesi Farmaceutici S.p.A, Mylan N.V., Orion Corporation, Sunovion Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Circassia Group PLC, Kyowa Kirin Co. Ltd., Sanofi S.A, Theravance Biopharma Inc., Verona Pharmaceuticals plc, Alcon Laboratories Inc., Amgen Inc., Apotex Inc., Aurobindo Pharma Limited, Biocon Limited, Biogen Inc., Bristol-Myers Squibb Company, Cipla Limited, Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals plc, Lupin Limited, Meda AB, Mundipharma International Limited, Pfizer Inc.
What Are the Primary Growth Drivers in the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
The escalating incidence of lung diseases is anticipated to boost the expansion of the chronic obstructive pulmonary disease (COPD) treatment market. Lung illnesses represent conditions that hinder the normal functioning of the lungs. The most prevalent diseases of this nature include asthma, COPD, and lung cancer. COPD treatments are essentially used to manage lung diseases, mitigate their progression, manage symptoms, and prevent further damage to the lungs via the use of medications and inhalers. For context, in September 2022, the US-based non-profit Global initiative for Chronic obstructive lung disease (GOLD) reported annual deaths from COPD at 3.2 million, with an estimated 200 million people being affected by the disease. Furthermore, asthma reportedly affected 262 million people worldwide in the same year, with the number anticipated to escalate in coming years. Similarly, predictions for 2023 by the LUNGevity Foundation, another US-based non-profit, indicate that lung cancer will be responsible for the annual death of 127,000 Americans. Consequently, the rising frequency of lung diseases is fueling the growth of the chronic obstructive pulmonary disease (COPD) treatment market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=10054&type=smp
What Are the Leading Segments in the Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Industry?
The chronic obstructive pulmonary disease (COPD) treatment market covered in this report is segmented –
1) By Drug Class: Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics, Other Drug Classes
2) By Type: Chronic Bronchitis, Emphysema
3) By End-User: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Combination Therapy: Long-Acting Beta-Agonists (LABA) + Inhaled Corticosteroids (ICS), Long-Acting Muscarinic Antagonists (LAMA) + LABA, Triple Therapy (LAMA + LABA + ICS)
2) By Bronchodilators: Short-Acting Beta-Agonists (SABA), Long-Acting Beta-Agonists (LABA), Long-Acting Muscarinic Antagonists (LAMA)
3) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Injectable Corticosteroids
4) By Phosphodiesterase Type 4 Inhibitor: Roflumilast, Other PDE4 Inhibitors
5) By Mucokinetics: Expectorants, Mucolytics
6) By Other Drug Classes: Antibiotics, Antivirals, Antifungal Agents
What Are the Key Market Trends in the Chronic Obstructive Pulmonary Disease (COPD) Treatment Industry?
The COPD treatment market is experiencing a rising trend of product innovation. To maintain their market positions, industry leaders in the COPD treatment market are creating cutting-edge products. As an example, GlaxoSmithKline plc (GSK), a pharmaceutical and biotechnology firm based in the UK, introduced Trelegy Ellipta, the first single-inhaler triple treatment for COPD patients in India in April 2022. Adaptable for anyone aged 18 or above, Trelegy Ellipta serves as a steady treatment option to manage and halt COPD symptoms. Its functionality mirrors natural corticosteroid hormones, as it influences immune system activity by binding to specific immune cell receptors. Furthermore, it assists in reducing lung airway inflammation, making breathing more manageable.
Access The Full Report Here:
What Is the Regional Outlook for the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
North America was the largest region in the chronic obstructive pulmonary disease (COPD) treatment market in 2024.Asia-Pacific is expected to be the global chronic obstructive pulmonary disease (COPD) treatment market report during the fastest-growing region in the forecast period. The regions covered in the chronic obstructive pulmonary disease (COPD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10054
This Report Delivers Insight On:
1. How big is the chronic obstructive pulmonary disease (copd) treatment market, and how is it changing globally?
2. Who are the major companies in the chronic obstructive pulmonary disease (copd) treatment market, and how are they performing?
3. What are the key opportunities and risks in the chronic obstructive pulmonary disease (copd) treatment market right now?
4. Which products or customer segments are growing the most in the chronic obstructive pulmonary disease (copd) treatment market?
5. What factors are helping or slowing down the growth of the chronic obstructive pulmonary disease (copd) treatment market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
